Literature DB >> 23269570

Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker.

Sang-Hoon Lee1, Eun Jung Lee, Sang Wan Chung, Ran Song, Joo-Young Moon, Sang-Ho Lee, Sung-Jig Lim, Yeon-Ah Lee, Seung-Jae Hong, Hyung-In Yang.   

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the spine and sacroiliac joint and rarely the kidneys. This study aimed to define the clinical and histological features and biology of renal disease in AS. We reviewed the medical records of 681 patients diagnosed with AS from November 2008 to November 2009. Baseline characteristics and laboratory and urinalysis results were reviewed. We identified patients with proteinuria or hematuria and analyzed their risk factors. After providing informed consent, 6 patients underwent a renal biopsy to determine the cause of proteinuria or hematuria. Of the 681 enrolled patients, 547 were men and 134 were women; 81 % were HLA B27 positive, and 8 % had abnormal urinalysis findings (proteinuria, 5.9 %; hematuria, 2.8 %; both, 0.7 %). Incidences of peripheral arthritis and uveitis were 29 % and 18.6 %, respectively. Immunoglobulin (Ig)A and uric acid levels were significantly different between patients with and without proteinuria. Erythrocyte sedimentation rate (ESR), total cholesterol, creatinine, and C-reactive protein (CRP) levels were not statistically significantly different between the 2 groups nor were there any significant differences in IgA, uric acid, ESR, total cholesterol, creatinine, and CRP levels between patients with and without hematuria. Six patients who had >1 g/day proteinuria underwent a renal biopsy; 2 were diagnosed with IgA nephropathy, 1 with amyloidosis, and 3 with non-specific glomerulonephropathy. In the amyloidosis patient, severe proteinuria was the dominant feature. For patients with renal amyloidosis and other forms of glomerulonephritis who initially had normal creatinine levels, tumor necrosis factor (TNF)-alpha blocker therapy resolved proteinuria, but this was not the case for patients with initial renal insufficiency. Renal involvement is not a rare complication of AS, and prognoses differ depending on kidney pathology. Serum levels of uric acid and IgA may predict renal involvement in AS. In cases where abnormal urine sediment is identified, renal biopsy is required to determine prognosis and decide the treatment protocol. Baseline serum creatinine level is important for predicting treatment response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269570     DOI: 10.1007/s00296-012-2624-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

Review 1.  Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications.

Authors:  Abdellah El Maghraoui
Journal:  Eur J Intern Med       Date:  2011-07-13       Impact factor: 4.487

Review 2.  [Ankylosing spondylitis].

Authors:  Abdellah El Maghraoui
Journal:  Presse Med       Date:  2004-11-20       Impact factor: 1.228

3.  Prevalence of subclinical amyloidosis in ankylosing spondylitis.

Authors:  Gurmeet Singh; Niraj Kumari; Amita Aggarwal; Narendra Krishnani; Ramnath Misra
Journal:  J Rheumatol       Date:  2007-02       Impact factor: 4.666

4.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.

Authors:  R C Lawrence; C G Helmick; F C Arnett; R A Deyo; D T Felson; E H Giannini; S P Heyse; R Hirsch; M C Hochberg; G G Hunder; M H Liang; S R Pillemer; V D Steen; F Wolfe
Journal:  Arthritis Rheum       Date:  1998-05

Review 5.  Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports.

Authors:  E S Strobel; E Fritschka
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

6.  Renal involvement in ankylosing spondylitis (Bechterew's disease)

Authors:  A V Nabokov; M A Shabunin; A V Smirnov
Journal:  Nephrol Dial Transplant       Date:  1996-06       Impact factor: 5.992

Review 7.  Ankylosing spondylitis: an overview.

Authors:  J Sieper; J Braun; M Rudwaleit; A Boonen; A Zink
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

8.  Renal abnormalities in ankylosing spondylitis.

Authors:  M J Vilar; S E Cury; M B Ferraz; R Sesso; E Atra
Journal:  Scand J Rheumatol       Date:  1997       Impact factor: 3.641

Review 9.  Epidemiology of spondyloarthritis in the People's Republic of China: review of the literature and commentary.

Authors:  Swee Cheng Ng; Zetao Liao; David Tak Tan Yu; Edwin Shih Yen Chan; Like Zhao; Jieruo Gu
Journal:  Semin Arthritis Rheum       Date:  2007-03-13       Impact factor: 5.532

10.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01
View more
  17 in total

1.  Schisandrin B Improves the Renal Function of IgA Nephropathy Rats Through Inhibition of the NF-κB Signalling Pathway.

Authors:  Jian-Hua Qin; Jia-Ru Lin; Wen-Fei Ding; Wei-Hua Wu
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 2.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

Review 3.  [Prognosis and therapy of inflammatory rheumatic diseases : Impact of renal manifestations].

Authors:  M Zänker; C D Cohen; H D Rupprecht
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

4.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

5.  Spectrums and Prognosis of Kidney Disease in Patients with Ankylosing Spondylitis.

Authors:  Dafeng He; Rong Wang; Shaoshan Liang; Dandan Liang; Feng Xu; Caihong Zeng; Zheng Tang
Journal:  Kidney Dis (Basel)       Date:  2020-08-26

6.  Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects.

Authors:  Ane Krag Jakobsen; Lennart T H Jacobsson; Oliver Patschan; Johan Askling; Lars Erik Kristensen
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

7.  MEFV M694V mutation has a role in susceptibility to ankylosing spondylitis: A meta-analysis.

Authors:  Linqing Zhong; Hongmei Song; Wei Wang; Ji Li; Mingsheng Ma
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

8.  Axial Spondyloarthritis and Autosomal Dominant Polycystic Kidney Disease in Two Siblings: A Rare Cooccurrence.

Authors:  Ozan Volkan Yurdakul; Abdulkerim Furkan Tamer; Okan Küçükakkaş; Aylin Rezvani
Journal:  Case Rep Rheumatol       Date:  2018-03-04

9.  Membranous nephropathy in a patient with ankylosing spondylitis: A case report.

Authors:  Ruiying Chen; Fang Li; Qionghong Xie; Jun Xue; Lingyun Lai; Shaojun Liu; Liyin Zhang; Chuanming Hao
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

10.  Spondyloarthritis-Associated IgA Nephropathy.

Authors:  Nicolas Champtiaux; Frédéric Lioté; Khalil El Karoui; Cécile Vigneau; Corinne Miceli; Emilie Cornec-Le Gall; Philippe Rémy; Gabriel Choukroun; Fadi Fakhouri; Cyril Garrouste; Laurent Veillon; Evangeline Pillebout; Thierry Lobbedez; Vincent Vuiblet; Alain Wynckel; Thomas Guincestre; Eric Toussirot; Eric Thervet; Marion Rabant; Alexandre Karras
Journal:  Kidney Int Rep       Date:  2020-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.